LENZ Therapeutics Reports 2026 Revenue of $3.38 Million
Revenue fell 72.9% from $12.5 million a year earlier. Net loss widened to $30.97 million from $16.7 million, while diluted loss per share was $0.99 versus $0.59.
LENZ Therapeutics reported 2026 results with revenue of $3.38 million, down 72.9% from $12.5 million a year earlier, and a net loss of $30.97 million compared with a net loss of $16.7 million. Diluted loss per share was $0.99, versus $0.59 in the prior-year period.Financial Highlights¹ Reported as…